Coherus Oncology, Inc. (CHRS)
1.07
0.00 (0.00%)
USD |
NASDAQ |
Oct 09, 16:00
1.075
0.00 (0.00%)
Pre-Market: 20:00
Coherus Oncology Gross Profit Margin (Quarterly) : 64.33% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 64.33% |
| March 31, 2026 | 61.86% |
| December 31, 2025 | 61.24% |
| September 30, 2025 | 59.49% |
| June 30, 2025 | 56.98% |
| March 31, 2025 | 51.32% |
| December 31, 2024 | 51.08% |
| September 30, 2024 | 29.31% |
| June 30, 2024 | 70.90% |
| March 31, 2024 | -27.64% |
| December 31, 2023 | 6.44% |
| September 30, 2023 | 53.95% |
| June 30, 2023 | 56.18% |
| March 31, 2023 | 45.05% |
| December 31, 2022 | 66.37% |
| September 30, 2022 | 22.43% |
| June 30, 2022 | 81.25% |
| March 31, 2022 | 84.41% |
| December 31, 2021 | 82.36% |
| September 30, 2021 | 73.12% |
| June 30, 2021 | 79.92% |
| March 31, 2021 | 89.93% |
| December 31, 2020 | 88.67% |
| September 30, 2020 | 91.46% |
| June 30, 2020 | 92.01% |
| Date | Value |
|---|---|
| March 31, 2020 | 93.58% |
| December 31, 2019 | 92.85% |
| September 30, 2019 | 93.51% |
| June 30, 2019 | 98.88% |
| March 31, 2019 | 94.00% |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | 91.75% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -197.4% |
| Return on Assets | -47.99% |
| Return on Invested Capital | -118.6% |
| Profit Margin (Quarterly) | -233.1% |
| Operating Margin (Quarterly) | -226.0% |
| Return on Net Operating Assets | -221.5% |